The case for & against
Bull & Bear analysis
Bullish
Eli Lilly and Company (NYSE: LLY) is a leading global healthcare company focused on the discovery, development, manufacturing, and marketing of innovative pharmaceutical products. The company is recognized for its advancements in diabetes care and immunology, particularly through its pioneering GLP-1 drugs like Mounjaro and Zepbound. Eli Lilly stands at the forefront of the healthcare sector, targeting significant market segments such as obesity, autoimmune diseases, and diabetes, with an emphasis on growth avenues enabled by recent acquisitions and product expansions.
Bull says
- ↑Q2 adjusted EPS $8.38 beats $6.01 estimate; revenue $22.97B (+48% YoY).
- ↑Raised 2026 revenue guidance to $85–87B, signaling robust growth outlook.
- ↑Acquired Merida Biosciences for up to $2.88B, enhancing immunology pipeline.
- ↑FDA approved Mounjaro for cardiovascular risk reduction, broadening diabetes franchise.
- ↑High earnings yield and strong FCF/EV ratio underpin attractive valuation.
- ↑Consensus price target $1,292 indicates substantial upside potential.
Bear says
- ↓Shares fell 1.1% post-earnings, extending a 2.7% decline overall.
- ↓High short interest suggests investor skepticism and potential selling pressure.
- ↓Insider sales by executives signal caution on near-term outlook.
- ↓Heavy reliance on GLP-1 franchise risks revenue erosion from generics.
- ↓Integration risks in new immunology drugs may impede pipeline returns.
- ↓Negative profitability signal implies challenges converting sales into sustainable earnings.